Legend Biotech Corporation

NasdaqGS:LEGN Stock Report

Market Cap: US$7.4b

Legend Biotech Dividends and Buybacks

Dividend criteria checks 0/6

Legend Biotech does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-0.1%

Buyback Yield

Total Shareholder Yield-0.1%
Future Dividend Yield0%
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 15
Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

Sep 18

Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Aug 01
Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges

Jul 30

Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Jul 05
Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

May 14

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

May 13
Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)

Mar 15

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Mar 06
Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Legend Biotech: Solid Traction With Carvykti Rollout

Jan 29

Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Jan 16
Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Nov 09
Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Apr 12
Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Dec 14
An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Sep 27

Legend Biotech stock slides on proposed ADS offering

Jul 25

Legend Biotech ends Phase 1 trial for lymphoma candidate

Jul 07

News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Jun 05
News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

May 14
Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Mar 22
Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Legend Biotech: Carvykti Approval Makes For A Buy Opportunity

Mar 04

Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be

Mar 03
Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Dec 30
Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if LEGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LEGN's dividend payments have been increasing.


Dividend Yield vs Market

Legend Biotech Dividend Yield vs Market
How does LEGN dividend yield compare to the market?
SegmentDividend Yield
Company (LEGN)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.3%
Industry Average (Biotechs)2.3%
Analyst forecast (LEGN) (up to 3 years)0%

Notable Dividend: Unable to evaluate LEGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LEGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate LEGN's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LEGN has not reported any payouts.


Discover strong dividend paying companies